financetom
Business
financetom
/
Business
/
Form 8.3 - Ricardo PLC
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - Ricardo PLC
Sep 23, 2025 6:19 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Qube Research & Technologies Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Ricardo PLC ( RCDOF )

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

22-09-2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

25p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

740,671

1.19

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

740,671

1.19

0

0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

0

Details, including nature of the rights concerned and relevant percentages:

0

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit (GBp)

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. call option

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of securities

Exercise price per unit (GBp)

25p ordinary

equity swap

decreasing a long position

33

427.00

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit (GBp)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit
(GBp)

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

0

0

0

0

 

0

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

0

 

0

0

0

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(c) Attachments

Class of relevant security:

 

25p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

740,671

1.19

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

740,671

1.19

0

0.00

0

Class of relevant security:

 

25p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

740,671

1.19

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

740,671

1.19

0

0.00

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Qube Research & Technologies LTD

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell
May 14, 2024
08:30 AM EDT, 05/14/2024 (MT Newswires) -- Profound Medical ( PROF ) said Tuesday that it received US Food and Drug Administration clearance for its TULSA-AI Contouring Assistant for use with its TULSA-PRO system to treat prostate disease. The medical device company said that TULSA uses pixel-by-pixel precision and sound technology to kill diseased prostate tissue without damaging urinary or...
Franklin Electric Names Joe Ruzynski CEO
Franklin Electric Names Joe Ruzynski CEO
May 14, 2024
08:38 AM EDT, 05/14/2024 (MT Newswires) -- Franklin Electric ( FELE ) said Tuesday it named Joe Ruzynski chief executive officer and a member of its board, effective July 1. Ruzynski, 49, succeeds Gregg Sengstack, chief executive since 2014 and chair since 2015, who will continue as executive chair of the water and energy technology firm's board. Ruzynski previously served...
FMC Partners With Optibrium to Accelerate Pipeline
FMC Partners With Optibrium to Accelerate Pipeline
May 14, 2024
08:35 AM EDT, 05/14/2024 (MT Newswires) -- FMC Corporation ( FMC ) said Tuesday it is working with Optibrium to discover small molecules that can help with crop protection. Financial terms of the partnership were not disclosed. The agreement is part of FMC's strategic plan to accelerate the discovery and commercialization of the agriculture science company's pipeline. FMC will use...
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
May 14, 2024
May 14 (Reuters) - The U.S. Food and Drug Administration has declined to approve the expanded use of Dynavax Technologies' ( DVAX ) hepatitis B vaccine in patients undergoing hemodialysis, the company said on Tuesday. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved